Compare HTGC & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | BHVN |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 1.3B |
| IPO Year | N/A | 2022 |
| Metric | HTGC | BHVN |
|---|---|---|
| Price | $15.15 | $9.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $18.67 | ★ $29.08 |
| AVG Volume (30 Days) | 2.2M | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 12.62% | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $5.24 | N/A |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.70 | $7.48 |
| 52 Week High | $19.67 | $24.06 |
| Indicator | HTGC | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 46.23 |
| Support Level | $13.77 | $8.40 |
| Resistance Level | $19.63 | $10.28 |
| Average True Range (ATR) | 0.42 | 0.62 |
| MACD | 0.19 | 0.14 |
| Stochastic Oscillator | 92.63 | 56.57 |
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.